Monthly Archives: September 2016

Biotechnology is the application of biological organisms, cells, or molecules to create products or services for the betterment of humans.

The bachelor of science degree in biotechnology prepares students to tackle environmental, natural resource, agricultural and medical problems through training in molecular biology, cell biology, biochemistry, genetic engineering and related biological disciplines. As biotechnology is increasingly used to address such issues, it offers diverse career opportunities. The curriculum emphasizes the basic sciences with a strong foundation in biology, chemistry, calculus, and physics that prepares students for upper-level biology and chemistry courses, but encourages elective breadth in the social sciences, humanities, and environmental studies. The degree program provides sufficient breadth for a student to enter a clinical medical career, or other health profession. Students who complete this major will be qualified to enter the growing biotechnology-related job market or continue their studies in graduate or professional school.

The biotechnology major features a strong practical experience component. Each student is required to fulfill an internship, which could be in a local, national, or international company, medical unit, or government research laboratory. The objective of this internship is to give students experience working outside a purely academic setting. In addition, each student is required to perform one independent research project in a local, national, or international academic laboratory. The objective of the research requirement is to teach the student to develop and meet a research goal using the scientific method. During the senior year, each student is required to complete a senior project synthesis in which the results from either the internship or independent researchor bothwill be organized and presented as a seminar or poster.

See original here:
Biotechnology , Undergraduate Programs, SUNY-ESF

Sign Up today for our next free INFO SESSION!

Palm Beach State College offers two degree programs in biotechnology. Students may choose to enroll inthe Associate in Science (AS) degree, which prepares students for entry into the biotechnology workforce, academic research, and related industries; or a dual Associate in Arts (AA)/(AS) degree option, designed for pre-med and other students planning to transfer to a four-year university. Both the AS and dual AA/AS programs require students to complete a 4-month Biotech internship outside of the College that provides training in real-world academic or industry research.

Our award winning program is taught byPhD level scientific faculty and researchers committed to providing challenging courses to meet the needs of the growing biotech industry.

We also offera 19-credit Biotechnology College Credit Certificate (CCC) for studentswho already have a bachelor's degree and want to gain the in-demand skills employers require and the internship needed to get a high-tech job orto strengthen anapplication to graduate or medical school.

Palm Beach State's biotech business partnership, consisting of over 25 different biotech firms, allows our students unique internship opportunities which develop the skills and experience required for a successful career in the biotechnology field.

Information for Advisors and Prospective Students

To get started in our Biotechnology program or foradditional information pleasecontact:

Read the rest here:
Palm Beach State - Biotechnology

Degree Programs: Full-Time/Part-Time: Free-Standing M.A.

Columbia Universitys Master of Arts in Biotechnology trains students in modern aspects of molecular biology with a particular emphasis on approaches used in the biotechnology and pharmaceutical industries. The curriculum focuses on the basic principles of biotechnology and specific applications in various fields. The use of biotechnology to fight disease is emphasized.

Thirty (30) points of course work plus a masters thesis are required for the M.A. in Biotechnology. The coursework includes three core courses, intensive laboratory experience and elective courses selected from the Department of Biological Sciences and a variety of other departments according to the students specific interests. The thesis includes a review of a topic in biotechnology. The program can be completed by full-time students in one year including the summer term or at a reduced pace by part-time students.

Research career in biotechnology:Anyone interested in becoming a research scientist in biotechnology will benefit from this program. The program covers basic and advanced aspects of biotechnology and allows students to start careers in research and development in the pharmaceutical and biotechnology industries.

Moderate biology background: Students with a moderate biology background have the opportunity to extend their course work in biotechnology and biological sciences and continue in these fields.

Regulatory affairs: Those interested in regulatory affairs and management in the biotechnology industry are able to enhance their previous or future training in these fields with a firm scientific background.

Management, investment, and patent law: Professionals in management, investment and patent law in the biotechnology industry are able to extend their knowledge of the science behind this industry, enabling them to make better decisions regarding this rapidly developing field.

Students wishing to apply for an M.D. or Ph.D.: Students interested in M.D. or Ph.D. programs are able to explore the field of biotechnology with a relatively short time commitment and increase their prospects for admission to top programs.

Read the original here:
Biotechnology | Columbia University | Graduate School of Arts ...

Objective

Seeks capital appreciation.

Investing primarily in companies engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes and companies that benefit significantly from scientific and technological advances in biotechnology. Normally investing at least 80% of assets in securities of companies principally engaged in these activities. Normally investing primarily in common stocks.

Stock markets, especially foreign markets, are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Foreign securities are subject to interest rate, currency exchange rate, economic, and political risks. Focus funds can be more volatile because of their narrow concentration in a specific industry. The biotechnology industry can be significantly affected by patent considerations, intense competition, rapid technological change and obsolescence, and government regulation. The fund may have additional volatility because it can invest a significant portion of assets in securities of a small number of individual issuers.

This description is only intended to provide a brief overview of the mutual fund. Read the fund's prospectus for more detailed information about the fund.

Excerpt from:
FBIOX - Fidelity Select Biotechnology Portfolio | Fidelity ...

BIO is undertaking an aggressive effort to promote the value of biopharmaceutical innovations and ensure that all patients have access to the drugs they need. A vital component of this campaign is holding insurers and their allies accountable for standing in the way of that access. For months, weve blown the whistle on their discriminatory practices, high cost-sharing and cost-shifting, and their blatant falsehoods on whats driving their premium increases, and today, were introducing a ReadMore>

Last week, the Washington Post published an article titled Alzheimers Drug Trial Sparks Optimism which highlighted new findings from a paper published in Nature. They shared exciting news of positive early trial results for a potential new Alzheimers treatment. Overall this is the best news that weve had in my 25 years doing Alzheimers clinical research and it brings new hope for patients and families most affected by the disease, said one of the studys ReadMore>

Before innovative therapies can start helping patients, successful matches between investors and entrepreneurs seeking to develop new medicines must occur. Without access to capital, potentially lifesaving drugs will exist only as ideas. Every fall investors looking for good prospects in the biotech sector gather at the BIO Investor Forum in San Franciscothe birthplace of biotechnology and home to over 1,600 life sciences companies. Many of these companies and others from around the country come to ReadMore>

Casey Whitaker, Communications Coordinator, Animal Agriculture Alliance | 09/08/2016

I have always been a perfectionist when it comes to my work, so its no surprise I found my passion in an industry that also strives for perfection. Animal agriculture never stops reaching for the highest quality of animal care, environmental stewardship and food safety possible. The industry strives for perfection, but also knows that perfection is hard to come by in agriculture because farmers, ranchers, veterinarians and all those involved in the farm-to-fork process ReadMore>

Hans Sauer, Deputy General Counsel, Intellectual Property, Legal, BIO | 09/07/2016

The topic of inter partes reviews (IPRs) has dominated conversation in patent circles for the last several years (see our archive for some of our past articles on the subject). As uncertainty grows in the biopharma community about IPR procedures and the future of innovation, BIO will make IPRs a major topic of discussion at our upcoming IP and Diagnostics Symposium (BIO IPDX) as well as BIOs IP Counsels Committee Meeting in November. An administrative ReadMore>

More here:
BIOtechNow